Cas:67593-46-8 Methyl 2-(2-chlorobenzylidene)-3-oxobutanoate manufacturer & supplier

Chemical Name:Methyl 2-(2-chlorobenzylidene)-3-oxobutanoate

CAS.NO:67593-46-8

Synonyms:MFCD06658526;methyl 2-[(2-chlorophenyl)methylidene]-3-oxobutanoate

Molecular Formula:C₁₂H₁₁ClO₃

Molecular Weight:238.66700

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:347.2ºC at 760 mmHg

Density:1.241 g/cm3

Index of Refraction:1.564

PSA:43.37000

Exact Mass:238.04000

LogP:2.48540

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like MFCD06658526 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl 2-[(2-chlorophenyl)methylidene]-3-oxobutanoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methyl 2-[(2-chlorophenyl)methylidene]-3-oxobutanoate Use and application,methyl 2-[(2-chlorophenyl)methylidene]-3-oxobutanoate technical grade,usp/ep/jp grade.

Related News: Russia, which shares a 2,600-mile border with China, reported its first two coronavirus cases on Friday. Methyl 2-(2-chlorobenzylidene)-3-oxobutanoate manufacturer Russia, which shares a 2,600-mile border with China, reported its first two coronavirus cases on Friday. Methyl 2-(2-chlorobenzylidene)-3-oxobutanoate supplier With the global industrial division of labor and the change in the business model of multinational pharmaceutical companies, the outsourced market for patented drug substances will further expand. Methyl 2-(2-chlorobenzylidene)-3-oxobutanoate vendor Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study. Methyl 2-(2-chlorobenzylidene)-3-oxobutanoate factory Russia, which shares a 2,600-mile border with China, reported its first two coronavirus cases on Friday.